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OBJECTIVES: An adverse consequence of cancer is venous thromboembolism(VTE),
manifesting as either deep vein thrombosis(DVT) or pulmonary embolism(PE). Com-
pared with non-cancer patients, the incidence of VTE has been increasing in cancer 
patients over the past ten years and the risk of recurrent DVT and subsequent
PE remains elevated. The aim of this study was to assess the cost-effectiveness of 
anticoagulant therapies to prevent VTE in Mexican patients with cancer from the 
payer’s perspective. METHODS: A six-state Markov model was performed to estimate
health and economic consequences during a time horizon of one year (1-week cycles).
Effectiveness measures were reduction in recurrent hospitalizations, reduced PE
and DVT events; and avoidance of deaths. Markov transition probabilities
were obtained from a meta-analysis employing international published literature. 
Comparators employed were warfarin(5 mg/day); dalteparin(2500,5000,7500 IU/
day); enoxaparin(20,40,60 mg/day); nadroparin(5700 IU/day); unfractionated heparin
plus warfarin(10000,30000,42000 IU/day5 mg/day); acenocoumarol(4 mg/day); and
no prophylaxis intervention. Resource use and costs were collected from clinical
records (n  7000) from Social Security Mexican Institute (IMSS) hospitals and ofﬁ cial 
institutional databases. The model was validated. Bootstrapping techniques were used 
to develop probabilistic sensitivity analyses. Acceptability curves were constructed. 
RESULTS: Incidence of PE and DVT were signiﬁ cant lower for patients treated with
dalteparin(p  0.05). Regarding the reduction of DVT events, dalteparin 2500, 5000 
and 7000 IU/day showed an Incremental cost-effectiveness ratio[CI95%] of 
US$45.81[US$44.9–US$46.8]; US$40.9[US$40.0–US$41.7] and US$37.8[US$37.0–
US$38.5] against warfarin (gold-standard), respectively. Nevertheless, enoxaparin 
in all its presentations and no prophylaxis intervention alternatives were dominated
by dalteparin. Dalteparin showed the lowest number of deaths and hospitalization 
re-admissions(for DVT and PE) when compared to other anticoagulant therapies
(p  0.05) and showed a trend toward signiﬁ cant reduction of institutional costs in 
the short term. Second-order Monte Carlo sensitivity analyses showed the robustness
of these results (ellipse-method). CONCLUSIONS: Dalteparin demonstrated to be a 
cost-effective anticoagulant therapy to reduce incidence of PE and DVT events, deaths
and recurrent hospitalizations in patients with cancer.
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OBJECTIVES: Dabigatran etexilate (DBG) is a new direct thrombin inhibitor which 
is administered orally at a ﬁ xed dose. EMEA has approved DBG at a standard dose
of 220 mg once daily (od), and at a lower dose of 150 mg od for patients aged over 
75. Recent economic analyses for the UK have demonstrated that DBG 220 mg od is 
cost-saving when compared with the commonly used agent, enoxaparin 40 mg od,
with comparable efﬁ cacy and safety. This analysis investigates the cost-effectiveness 
of DBG 150 mg od for the prevention of venous thromboembolism (VTE) in the subset
of patients aged over 75 undergoing total hip arthroplasty (THA) or total knee 
arthroplasty (TKA) from the perspective of the UK National Health Service. 
METHODS: There was a comparison of DBG 150 mg od to enoxaparin 40 mg od 
using a decision model. Relative risks for VTE and bleeding events speciﬁ c to patients 
aged over 75 were derived from sub-group analyses of the phase III DBG trials, RE-
MODEL and RE-NOVATE. Probabilities of recurrent VTE and post-thrombotic syn-
drome were estimated from published longitudinal studies. RESULTS: DBG was less
costly than enoxaparin in TKR and substantially less so in THR, primarily due to 
differences in administration costs. VTE and bleeding rates were similar for DBG and 
enoxaparin; the probability of cost-effectiveness was 89% in TKR and 99% in THR 
at a willingness-to-pay threshold of a20,000 per quality-adjusted life-year. These 
results were robust across a range of sensitivity analyses. CONCLUSIONS: Throm-
boprophylaxis with DBG 150 mg od in patients aged over 75 years is cost saving 
compared to enoxaparin 40 mg od, with comparable efﬁ cacy and safety.
PCV55
COST-EFFECTIVENESS OF VALSARTAN IN JAPAN: RESULTS
FROM THE JIKEI HEART STUDY
Shimizu M1, Crawford B2, Ikewaki K1, Taniguchi I1, Kamae I3, Dahlof B4, Drost P5, 
Mochizuki S1
1Jikei University School of Medicine, Tokyo, Tokyo, Japan, 2Mapi Values, Tokyo, Meguro, Japan, 
3Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 
4Sahlgrenska University Hospital, Gothenburg, Gothenburg, Sweden, 5Mapi Values, AX
Houten, AX Houten, Netherlands
OBJECTIVES: The Jikei Heart Study (n  3081) demonstrated that the angiotensin II 
receptor blocker (ARB) valsartan signiﬁ cantly reduced the incidence of the primary 
composite endpoint in Japanese patients previously receiving standard non-ARB
therapy. The primary end point was a composite of CV morbidity/mortality including
stroke or transient ischemic attack, hospitalization for heart failure or angina, dissect-
ing aneurysm of the aorta, lower-limb arterial obstruction, doubling of serum creati-
nine, and transition to dialysis. The purpose of this study was to determine whether 
valsartan is cost-effective based on data from the Jikei Heart Study. METHODS: A
probabilistic model assessed the cost-effectiveness of valsartan vs. standard therapy in 
a Japanese patient population. Cost-effectiveness analyses incorporated life-years 
gained and quality-adjusted-life-years gained to adjust for impairment of quality-of-
life. Conservative “cost accounting” of the Jikei Heart Study was employed to validate
model results—direct medical costs associated with in- and out-patient treatment of 
patients. A probabilistic sensitivity analysis assessed the robustness of the results. 
RESULTS: Expected total costs for the non-ARB arm were ¥365,961 per patient for 
three years compared to ¥365,151 per patient for three years for valsartan—a cost-
savings of ¥270 per patient per year. Valsartan would also extend quality adjusted life
years (QALY) by 0.09 over non-ARB treatment in the 3-year time horizon. The cost 
savings and increased QALYs lead to a ¥85,215 per QALY gained, a dominant 
strategy. Probabilistic sensitivity analyses demonstrated robustness of the economic 
evaluation. CONCLUSIONS: Valsartan is cost-effective in Japanese patients with high 
blood pressure, coronary heart disease and/or heart failure, who previously received 
standard care. Including costs associated with National Health Insurance sickness 
allowance for extended disability, valsartan is both more effective and less costly than 
non-ARB treatment.
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OBJECTIVES: Dabigatran etexilate (DBG) is a new direct thrombin inhibitor which 
is administered orally at a ﬁ xed dose. Patients with renal impairment are thought to 
be at higher risk of bleeding during thromboprophylaxis, and lower doses are recom-
mended in this population. EMEA has approved DBG at a standard dose of 220 mg 
once daily (od), and at a lower dose of 150 mg od for patients with moderate renal 
impairment. Recent economic analyses for the UK have demonstrated that DBG 
220 mg od is cost-saving when compared with the commonly used agent, enoxaparin
40 mg od, with comparable efﬁ cacy and safety. This analysis investigates the cost-
effectiveness of DBG 150 mg od for the prevention of venous thromboembolism (VTE) 
in patients with moderate renal impairment undergoing total hip arthroplasty (THA)
or total knee arthroplasty (TKA) from the perspective of the UK National Health
Service. METHODS: DBG 150 mg od was compared to enoxaparin 40 mg od using 
a decision model. Relative risks for VTE and bleed events speciﬁ c to patients with 
moderate renal impairment (creatinine clearance q30 and 50 mL/min) were derived 
from sub-group analyses of the phase III DBG trials, RE-MODEL and RE-NOVATE. 
Probabilities of recurrent VTE and post-thrombotic syndrome were estimated from 
published longitudinal studies. RESULTS: DBG was less costly than enoxaparin in
TKR and substantially less so in THR, primarily due to differences in administration 
costs. VTE and bleeding rates were similar for DBG and enoxaparin; the probability
of cost-effectiveness was 75% in TKR and 97% in THR at a willingness-to-pay 
threshold of £20,000 per quality-adjusted life-year. These results were robust across
a range of sensitivity analyses. CONCLUSIONS: Thromboprophylaxis with DBG 
150 mg od in patients with moderate renal impairment is cost saving compared to 
enoxaparin 40 mg od, with comparable efﬁ cacy and safety.
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OBJECTIVES: To perform health economic evaluation of iso-osmolar Iodixanol vs. 
low-osmolar contrast media in patients undergoing coronarography. METHODS: The 
decision tree modeling was performed using literature data on dosage, efﬁ cacy and
safety. Iopromide as one of the commonly used low-osmolar contrast in Russia was 
chosen for comparison. Efﬁ cacy of Iodixanol and Iopromide was equal, so only safety
issues were taken into consideration. Costs of procedure including side effects manage-
ment were calculated using experts interview in Moscow clinics and hospital cost 
estimates. Cost-minimization analysis (CMA) from health care system perspective was 
performed. RESULTS: According to McCullough PA, et al. (2006) the rate of contrast-
induced nephropathy (CIN) was 1.4% for Iodixanol and 3.5% for Iopromide in 
common population, 2.8% and 8.4% in patients with chronic kidney disease (CKD), 
and 3.5% and 15.5% in patients with diabetes mellitus combined with CKD. Rihal 
CS and colleagues (2002) showed that CIN patients required haemodialysis in 7.9%.
They demonstrated 22% mortality compared to 1.4% of patients with normal renal 
function. Hypotension rate was 20.1% and 9.1%, acute heart failure was 11.4%
and 3.1%, cardiac arrest was 11.4% and 1.5%, respiratory distress-syndrome 
was 9.4% and 0.7%, and myocardial infarction was 3.9% and 0.9% respectively.
